Special Drug Use-results Surveillance of Scemblix Tablets

Brief summary (registry, in English)

Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.

What you commit to

• Study type: Observational
• Participants enrolled: 550
• From 4 Jul 2022 to the primary completion date, 29 Feb 2024
• 180 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: - to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (180)

Sites in registry order. Pick your city on the disease page to sort them by distance.